Recurrence Risk Evaluation by 21-gene Detection

Xijing Hospital220 enrolled

Overview

Breast cancer patients with early breast cancer were enrolled according to the inclusion criteria. Baseline characteristics were recorded from medical record system. Recurrence score were obtained by 21-gene detection kits from different biological companies. Relationship between recurrence score and the prognosis was explored. Meanwhile, the investigators analyzed the consistency of the results obtained from various 21-gene test kits and immunohistochemistry detection.

Study Type

OBSERVATIONAL

Enrollment

220

Conditions

Relationship and Consistency Analysis

Interventions

recurrence risk evaluationDIAGNOSTIC_TEST

Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. breast cancer in stage I-III, tumor size\>0.5cm 2. lymph nodes negative 3. hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+） 4. HER2 negative（IHC 0 or +， FISH negative） 5. receive endocrine therapy only 6. enough FFPE samples within 10 years（3\~6 10μm ） 7. patients with integrated medical records Exclusion Criteria: 1. Tumor cells \<5% 2. Isolated RNA\<500ng

Locations (1)

Xijing hoapital

Xi'an, China

Outcomes

Primary Outcomes

correlation analysis

x2 value and P value of chi-square test

Time frame: Janyary 1, 2019-December 31, 2019

Secondary Outcomes

consistency analysis

kappa value, P value of consistency analysis

Time frame: Janyary 1, 2019-December 31, 2019

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.